$0.80 Earnings Per Share Expected for Valeant Pharmaceuticals Intl Inc (VRX) This Quarter

Equities research analysts expect that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) will announce $0.80 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Valeant Pharmaceuticals Intl’s earnings, with estimates ranging from $0.71 to $0.87. Valeant Pharmaceuticals Intl reported earnings per share of $1.05 during the same quarter last year, which suggests a negative year over year growth rate of 23.8%. The company is scheduled to report its next earnings results on Tuesday, August 14th.

According to Zacks, analysts expect that Valeant Pharmaceuticals Intl will report full year earnings of $3.33 per share for the current year, with EPS estimates ranging from $3.00 to $3.60. For the next year, analysts expect that the firm will post earnings of $3.54 per share, with EPS estimates ranging from $3.31 to $3.94. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Valeant Pharmaceuticals Intl.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.60 by $0.29. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter last year, the company posted $1.79 earnings per share. Valeant Pharmaceuticals Intl’s revenue was down 5.4% on a year-over-year basis.

A number of research analysts recently commented on VRX shares. Deutsche Bank lifted their price target on shares of Valeant Pharmaceuticals Intl from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, April 30th. TD Securities lifted their price target on shares of Valeant Pharmaceuticals Intl from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, May 9th. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Tuesday, May 8th. Jefferies Financial Group lifted their price target on shares of Valeant Pharmaceuticals Intl to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, May 9th. Finally, Mizuho upgraded shares of Valeant Pharmaceuticals Intl from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 15th. Five investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $21.43.

Shares of VRX traded up $0.07 during mid-day trading on Tuesday, reaching $23.00. 2,242,200 shares of the company’s stock traded hands, compared to its average volume of 10,250,916. The stock has a market cap of $8.12 billion, a PE ratio of 6.01, a price-to-earnings-growth ratio of 0.35 and a beta of -0.38. The company has a current ratio of 1.18, a quick ratio of 0.92 and a debt-to-equity ratio of 5.59. Valeant Pharmaceuticals Intl has a 12 month low of $10.94 and a 12 month high of $27.79.

In related news, Director Schutter Richard U. De bought 15,000 shares of the firm’s stock in a transaction on Tuesday, May 15th. The stock was bought at an average price of $21.83 per share, with a total value of $327,450.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 11.54% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its position in Valeant Pharmaceuticals Intl by 189.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after acquiring an additional 3,921 shares during the last quarter. Prime Capital Investment Advisors LLC acquired a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $142,000. Assetmark Inc. lifted its position in Valeant Pharmaceuticals Intl by 409.4% during the 1st quarter. Assetmark Inc. now owns 11,498 shares of the specialty pharmaceutical company’s stock worth $183,000 after acquiring an additional 9,241 shares during the last quarter. First Allied Advisory Services Inc. lifted its position in Valeant Pharmaceuticals Intl by 33.6% during the 1st quarter. First Allied Advisory Services Inc. now owns 15,101 shares of the specialty pharmaceutical company’s stock worth $242,000 after acquiring an additional 3,800 shares during the last quarter. Finally, Zweig DiMenna Associates LLC acquired a new position in Valeant Pharmaceuticals Intl during the 1st quarter worth $245,000. 46.95% of the stock is owned by institutional investors and hedge funds.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Get a free copy of the Zacks research report on Valeant Pharmaceuticals Intl (VRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply